Literature DB >> 18090537

Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex.

Michael H Olsen1, Tine W Hansen, Marina K Christensen, Finn Gustafsson, Susanne Rasmussen, Kristian Wachtell, Hans Ibsen, Christian Torp-Pedersen, Per R Hildebrandt.   

Abstract

BACKGROUND: Previous studies have shown that the urine albumin/creatinine ratio (UACR), high sensitivity C-reactive protein (hsCRP) and N-terminal pro brain natriuretic peptide (Nt-proBNP) predict cardiovascular events in a general population aged 41, 51, 61 or 71 years. This study investigated the impact of age and sex on their prognostic performance in a subgroup of 1994 apparently healthy individuals without diabetes, previous stroke or myocardial infarction, who did not receive any cardiovascular, antidiabetic or lipid-lowering medication.
METHODS: In 1993-1994 we recorded cardiovascular risk factors, UACR, hsCRP and Nt-proBNP. The composite cardiovascular endpoint (CEP) of cardiovascular death and non-fatal stroke or myocardial infarction was assessed after 9.5 years.
RESULTS: In Cox regression analyses predicting CEP, the effects of log(hsCRP) and log(Nt-proBNP) were modulated by sex (P < 0.05) and age (P < 0.05), respectively. The effect of logUACR was not significantly modulated by age or sex. Log(hsCRP)/SD did not predict CEP in women, but did predict CEP in 41 plus 51-year-old men [hazard ratio (HR) 1.71; 95% confidence interval, 1.1-2.6; P < 0.05] and 61 plus 71-year-old men (HR 1.64; 1.3-2.2; P < 0.001). Log(Nt-proBNP)/SD predicted CEP in 61 plus 71-year-old women (HR 1.74; 1.2-2.5; P < 0.01) and in 61 plus 71-year-old men (HR 1.58; 1.3-2.0; P < 0.001).
CONCLUSION: Elevated hsCRP, reflecting early atherosclerosis, predicted CEP even in 41 plus 51-year-old men. Elevated Nt-proBNP, reflecting subclinical cardiovascular damage, predicted CEP in 61 plus 71-year-old subjects. Elevated UACR, reflecting endothelial dysfunction as well as microvascular damage, predicted events independently of age and sex, but primarily in 61 plus 71-year-old subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18090537     DOI: 10.1097/HJH.0b013e3282f18301

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  High-sensitivity C-reactive protein predicts adverse cardiovascular events in patients with Takayasu arteritis with coronary artery involvement.

Authors:  X Wang; A Dang; N Lv; Q Liu; B Chen
Journal:  Clin Rheumatol       Date:  2015-02-10       Impact factor: 2.980

2.  N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort.

Authors:  Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai
Journal:  Stroke       Date:  2014-04-22       Impact factor: 7.914

3.  Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review.

Authors:  Andrew C Don-Wauchope; Pasqualina L Santaguida; Robert McKelvie; Judy A Brown; Mark Oremus; Usman Ali; Amy Bustamam; Nazmul Sohel; Stephen A Hill; Ronald A Booth; Cynthia Balion; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

Review 4.  Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases.

Authors:  Da-Rong Pu; Jun R Chiong; Qi-chang Zhou
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

5.  Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender : Results from the PROBE-HF study.

Authors:  Piercarlo Ballo; Irene Betti; Alessandro Barchielli; Daniela Balzi; Gabriele Castelli; Leonardo De Luca; Mihai Gheorghiade; Alfredo Zuppiroli
Journal:  Clin Res Cardiol       Date:  2015-11-07       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.